ValuEngine downgraded shares of Galapagos (NASDAQ:GLPG) from a hold rating to a sell rating in a research report released on Friday.
Other equities analysts also recently issued research reports about the stock. Cowen reissued a buy rating on shares of Galapagos in a research note on Thursday, August 10th. Nomura increased their price objective on shares of Galapagos from $108.00 to $124.00 and gave the company a buy rating in a research note on Friday, August 11th. Stifel Nicolaus raised shares of Galapagos from a hold rating to a buy rating and increased their price objective for the company from $83.00 to $101.00 in a research note on Friday, August 11th. BTIG Research reissued a buy rating and issued a $118.00 price objective on shares of Galapagos in a research note on Monday, November 20th. Finally, BidaskClub raised shares of Galapagos from a sell rating to a hold rating in a research note on Thursday, August 17th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. The company has an average rating of Hold and a consensus price target of $111.00.
Shares of Galapagos (NASDAQ:GLPG) traded down $0.66 during trading hours on Friday, reaching $86.59. 41,267 shares of the company traded hands, compared to its average volume of 150,622. Galapagos has a fifty-two week low of $57.86 and a fifty-two week high of $104.12.
Hedge funds have recently added to or reduced their stakes in the company. Advisors Preferred LLC bought a new position in shares of Galapagos during the third quarter valued at $105,000. New York State Common Retirement Fund bought a new position in shares of Galapagos during the second quarter valued at $166,000. Acadian Asset Management LLC bought a new position in Galapagos during the second quarter worth $166,000. Pacad Investment Ltd. bought a new position in Galapagos during the second quarter worth $168,000. Finally, Envestnet Asset Management Inc. raised its stake in Galapagos by 156.6% during the third quarter. Envestnet Asset Management Inc. now owns 1,742 shares of the biotechnology company’s stock worth $177,000 after buying an additional 1,063 shares during the last quarter. 19.71% of the stock is owned by hedge funds and other institutional investors.
WARNING: “Galapagos (GLPG) Downgraded by ValuEngine” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/04/galapagos-glpg-downgraded-by-valuengine.html.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.